MPLT
MapLight Therapeutics, Inc.
Biotechnology
Market Cap$1.33B
5Y Perf.+10.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MPLT vs ACLX
Revenue, margins, valuation, and 5-year total return — side by side.
ACLX
Arcellx, Inc.
Biotechnology
Market Cap$6.73B
5Y Perf.+46.9%
MPLT vs ACLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MPLT | ACLX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.33B | $6.73B |
| Revenue (TTM) | $0.00 | $22M |
| Net Income (TTM) | $-103M | $-229M |
| Gross Margin | — | -64.8% |
| Operating Margin | — | -11.4% |
| Total Debt | $7M | $96M |
| Cash & Equiv. | $38M | $80M |
Quick Verdict: MPLT vs ACLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MPLT and ACLX are tied at the top with 2 categories each — the right choice depends on your priorities. Arcellx, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
MPLT
MapLight Therapeutics, Inc.
The Growth Play
MPLT has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- EPS growth -39.6%
- Low D/E 5.7%, current ratio 7.20x
- current ratio 7.20x
Best for: growth exposure and sleep-well-at-night
ACLX
Arcellx, Inc.
The Long-Run Compounder
ACLX is the clearest fit if your priority is long-term compounding.
- 5.8% 10Y total return vs MPLT's 62.6%
- +95.0% vs MPLT's +62.6%
- -36.2% ROA vs MPLT's -69.7%, ROIC -46.2% vs -153.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | MPLT | 3.3% margin vs ACLX's -10.3% |
| Stability / Safety | MPLT | Lower D/E ratio (5.7% vs 23.9%) |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACLX | +95.0% vs MPLT's +62.6% |
| Efficiency (ROA) | ACLX | -36.2% ROA vs MPLT's -69.7%, ROIC -46.2% vs -153.7% |
MPLT vs ACLX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACLXLAGGINGMPLT
MPLTMapLight Therapeutics…
0leads
ACLXArcellx, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs MPLTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
ACLX6/6
Risk & VolatilityBeta, volatility, and downside exposure
ACLX1/1
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
ACLX and MPLT operate at a comparable scale, with $22M and $0 in trailing revenue.
| Metric | MPLTMapLight Therapeu… | ACLXArcellx, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $22M |
| EBITDAEarnings before interest/tax | -$108M | -$246M |
| Net IncomeAfter-tax profit | -$103M | -$229M |
| Free Cash FlowCash after capex | -$113M | -$213M |
| Gross MarginGross profit ÷ Revenue | — | -64.8% |
| Operating MarginEBIT ÷ Revenue | — | -11.4% |
| Net MarginNet income ÷ Revenue | — | -10.3% |
| FCF MarginFCF ÷ Revenue | — | -9.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -89.2% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -13.6% |
Insufficient data to determine a leader in this category.
Valuation Metrics
Evenly matched — MPLT and ACLX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MPLTMapLight Therapeu… | ACLXArcellx, Inc. |
|---|---|---|
| Market CapShares × price | $1.3B | $6.7B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $6.7B |
| Trailing P/EPrice ÷ TTM EPS | -15.66x | -28.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 302.09x |
| Price / BookPrice ÷ Book value/share | 10.53x | 16.10x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MPLT and ACLX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — MPLT and ACLX each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
ACLX delivers a -55.4% return on equity — every $100 of shareholder capital generates $-55 in annual profit, vs $-2 for MPLT. MPLT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACLX's 0.24x. On the Piotroski fundamental quality scale (0–9), MPLT scores 4/9 vs ACLX's 1/9, reflecting mixed financial health.
| Metric | MPLTMapLight Therapeu… | ACLXArcellx, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -55.4% |
| ROA (TTM)Return on assets | -69.7% | -36.2% |
| ROICReturn on invested capital | -153.7% | -46.2% |
| ROCEReturn on capital employed | -83.9% | -46.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.06x | 0.24x |
| Net DebtTotal debt minus cash | -$32M | $16M |
| Cash & Equiv.Liquid assets | $38M | $80M |
| Total DebtShort + long-term debt | $7M | $96M |
| Interest CoverageEBIT ÷ Interest expense | — | -8.45x |
Evenly matched — MPLT and ACLX each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ACLX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACLX five years ago would be worth $68,494 today (with dividends reinvested), compared to $16,263 for MPLT. Over the past 12 months, ACLX leads with a +95.0% total return vs MPLT's +62.6%. The 3-year compound annual growth rate (CAGR) favors ACLX at 38.4% vs MPLT's 17.6% — a key indicator of consistent wealth creation.
| Metric | MPLTMapLight Therapeu… | ACLXArcellx, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +62.6% | +81.7% |
| 1-Year ReturnPast 12 months | +62.6% | +95.0% |
| 3-Year ReturnCumulative with dividends | +62.6% | +164.8% |
| 5-Year ReturnCumulative with dividends | +62.6% | +584.9% |
| 10-Year ReturnCumulative with dividends | +62.6% | +584.9% |
| CAGR (3Y)Annualised 3-year return | +17.6% | +38.4% |
ACLX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
ACLX leads this category, winning 1 of 1 comparable metric.
Risk & Volatility
ACLX currently trades 99.9% from its 52-week high vs MPLT's 88.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MPLTMapLight Therapeu… | ACLXArcellx, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | — | -0.58x |
| 52-Week HighHighest price in past year | $33.28 | $115.13 |
| 52-Week LowLowest price in past year | $16.34 | $53.07 |
| % of 52W HighCurrent price vs 52-week peak | +88.0% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 59.2 | 79.9 |
| Avg Volume (50D)Average daily shares traded | 264K | 1.3M |
ACLX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Consensus price targets imply 15.4% upside for MPLT (target: $34) vs -2.3% for ACLX (target: $112).
| Metric | MPLTMapLight Therapeu… | ACLXArcellx, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | $33.80 | $112.45 |
| # AnalystsCovering analysts | — | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACLX leads in 2 of 6 categories — strongest in Total Returns and Risk & Volatility. 2 categories are tied.
Best OverallArcellx, Inc. (ACLX)Leads 2 of 6 categories
Loading custom metrics...
MPLT vs ACLX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MPLT or ACLX a better buy right now?
Analysts rate Arcellx, Inc.
(ACLX) a "Hold" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MPLT or ACLX?
Over the past 5 years, Arcellx, Inc.
(ACLX) delivered a total return of +584. 9%, compared to +62. 6% for MapLight Therapeutics, Inc. (MPLT). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus MPLT's +59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MPLT or ACLX?
On balance sheet safety, MapLight Therapeutics, Inc.
(MPLT) carries a lower debt/equity ratio of 6% versus 24% for Arcellx, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MPLT or ACLX?
On earnings-per-share growth, the picture is similar: MapLight Therapeutics, Inc.
grew EPS -39. 6% year-over-year, compared to -103. 5% for Arcellx, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MPLT or ACLX?
MapLight Therapeutics, Inc.
(MPLT) is the more profitable company, earning 0. 0% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MPLT leads at 0. 0% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MPLT or ACLX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MPLT or ACLX better for a retirement portfolio?
For long-horizon retirement investors, Arcellx, Inc.
(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 58), +584. 9% 10Y return). Both have compounded well over 10 years (ACLX: +584. 9%, MPLT: +59. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MPLT and ACLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.